Biomics Biopharma (ASX:BBM) Research & Development: A$ Mil (TTM As of . 20)


What is Biomics Biopharma Research & Development?

Biomics Biopharma ASX:BBM Research & Development is A$ Mil as of . 20.

Research & Development is the aggregate amount of research and development expenses during the year. Biomics Biopharma's Research & Development for the six months ended in . 20 was A$0.00 Mil. Biomics Biopharma does not have enough years/quarters to calculate the Research & Development for the trailing twelve months (TTM) ended in . 20.

Biomics Biopharma  (ASX:BBM) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Biomics Biopharma Research & Development Related Terms

Biomics Biopharma Research & Development Historical Data

* Premium members only.

The historical data trend for Biomics Biopharma's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biomics Biopharma Research & Development Chart

Biomics Biopharma Annual Data
Trend
Research & Development

Biomics Biopharma Semi-Annual Data
Research & Development

Biomics Biopharma Research & Development Calculation

This is the expense the company spent on research and development.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of A$ Mil mean?
Biomics Biopharma (ASX:BBM) has a Research & Development of A$ Mil as of . 20. Research and development expense is the total cost for research and development activities. View historical data on Biomics Biopharma and its competitors.
Is Biomics Biopharma's Research & Development too high?
Biomics Biopharma's current Research & Development is A$ Mil.
How does Biomics Biopharma's Research & Development compare to competitors?
Biomics Biopharma's Research & Development of A$ Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Biomics Biopharma and its competitors. Biomics Biopharma's current Research & Development is A$ Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biomics Biopharma stock overvalued right now?
Biomics Biopharma (ASX:BBM) has a current Research & Development of A$ Mil. The current Research & Development is A$ Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Biomics Biopharma (ASX:BBM), the current Research & Development is A$ Mil as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biomics Biopharma Business Description

Address 1 Macquarie Place, Level 36, Gateway Tower, Sydney, NSW, AUS, 2000
Biomics Biopharma Ltd is a near-clinical-stage biopharmaceutical company in developing and commercialising double stranded ribonucleic acid (dsRNA) based innovative products for unmet medical needs.